scholarly journals Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease

2017 ◽  
Vol 7 (4) ◽  
pp. 604-608 ◽  
Author(s):  
Hideyuki Niwa ◽  
Yoshiro Nakahara ◽  
Masanori Yokoba ◽  
Hisashi Mitsufuji ◽  
Jiichiro Sasaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Safety And Efficacy

scholarly journals Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Tomoyuki Araya ◽  
Toshiyuki Kita ◽  
Tsukasa Ueda ◽  
Nanao Terada ◽  
Tamami Sakai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Small Cell Lung ◽  
Safety And Efficacy

Background. Standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) with preexisting interstitial lung disease (ILD) has not yet been established. Although a combination of carboplatin and paclitaxel is most frequently used for patients with advanced NSCLC and ILD, the safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are yet to be elucidated. Objectives. This study aimed to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel for advanced NSCLC with ILD. Methods. This retrospective study included nine patients with advanced NSCLC and ILD who received carboplatin plus nab-paclitaxel as first-line chemotherapy at the National Hospital Organization Kanazawa Medical Center between April 2013 and December 2017. The ILD-GAP index was used to evaluate mortality risk of baseline ILD. Results. A usual interstitial pneumonia (UIP) pattern of ILD was observed in five (55.6%) patients on their baseline high-resolution computed tomography (HRCT) scans. The median ILD-GAP index was 4 (range, 1–5), and six (66.7%) patients had ILD-GAP index ≥4. We observed no ILD exacerbations or chemotherapy-related deaths. The overall response and disease control rates were 77.8% (95% CI, 40.0–97.2) and 88.9% (95% CI, 51.8–97.2), respectively. The median progression-free survival and overall survival were 5.8 months (95% CI, 2.1–7.7) and 8.0 months (95% CI, 2.6–16.8), respectively. Conclusions. Carboplatin plus nab-paclitaxel showed favorable safety and efficacy in patients who had advanced NSCLC and ILD with a high risk of mortality. Prospective studies are required to further confirm these results.

scholarly journals Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

2020 ◽  
Vol 59 (16) ◽  
pp. 1939-1945 ◽  
Author(s):  
Tetsuo Fujita ◽  
Tsuguko Kuroki ◽  
Nami Hayama ◽  
Yuka Shiraishi ◽  
Hiroyuki Amano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document